We are honored to announce that we’ve been chosen as a finalist for the prestigious Biotech Company of the Year at the CITELINE Japan Award 2024, which celebrates exceptional achievements and groundbreaking innovation in the pharmaceutical and biotech industries. Read More

日本経済新聞に当社の記事が掲載されました。「創薬のプリズムバイオラボに熱視線　メガファーマも評価」

TOKYO, Japan, 9 September 2024: — PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the interim analysis of a combination study of E7386, created through collaboration research with Eisai Co., Ltd., and Lenvatinib mesylate ( “lenvatinib”) will be presented...

We are pleased to announce the establishment of PRISM BioLab Co., Ltd. Tokyo office. The office was officially opened on September 2, 2024 and will serve as a base for our business and administrative functions, for enhanced communications with our investors and partners, and to enable more effective business decisions. We sincerely appreciate the continued...

PRISM BioLab Corporation is pleased to announce its initial listing on the Tokyo Stock Exchange Growth Market today. We would like to take this opportunity to express our sincere gratitude to all our stakeholders for their unwavering support and cooperation. For more details regarding our new listing, please visit the Tokyo Stock Exchange website. https://www.jpx.co.jp/listing/stocks/new/index.html...

PRISM BioLab is pleased to announce that the Tokyo Stock Exchange today approved the initial listing of our shares on the Growth Market of the Tokyo Stock Exchange. Read Full Press Release-Japanese Text Only　

TOKYO, Japan, 25 Apr 2024: — PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and licensing agreement with ONO PHARMACEUTICAL CO., LTD. . Read Full Press Release

株式分割に関する基準日設定公告（pdf）

TOKYO, Japan, 24 Jan 2024: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced a 1.5 billion yen ($10.3M) fundraise. Funds will be used to refine PRISM’s proprietary PepMetics® chemistry platform, expand biology and screening capabilities and advance internal pipeline of...

TOKYO, Japan, 28 Nov 2023: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a License and Collaboration Agreement with Eli Lilly and Company. Read Full Press Release